XML 73 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Commitments and contingencies - AbbVie Alpha Synuclein Collaboration Agreement - (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Feb. 28, 2019
USD ($)
item
Dec. 31, 2020
USD ($)
item
Dec. 31, 2019
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Deferred revenue   $ 43,689 $ 70,040
Revenue recognized   26,351  
AbbVie Alpha Synuclein Collaboration Agreement | AbbVie      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Number of antibodies encoded by virus | item 1    
Number of research antibodies | item 1    
Non-refundable upfront payment received $ 65,000    
First Research Compound payment 80,000    
Three additional research compounds payment to be received for each $ 30,000    
Number of additional research compounds | item 3    
Milestone payments to be received for licensed compound in case Parkinson's disease indication $ 450,000    
Milestone payments to be received for licensed compound in case first indication other than Parkinson's disease 185,000    
Milestone payments to be received for licensed compound for subsequent non-Parkinson's disease indication 92,500    
Revenue recognized   $ 58,900  
Allocation of Transaction Price      
Allocation of Transaction Price $ 65,000    
AbbVie Alpha Synuclein Collaboration Agreement | AbbVie | Minimum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Antibodies to include in Research Period | item 1    
The number of Licensed Products | item 1    
AbbVie Alpha Synuclein Collaboration Agreement | AbbVie | Maximum      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Antibodies to include in Research Period | item 4 4  
AbbVie Alpha Synuclein Collaboration Agreement | AbbVie | Research Services      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Revenue recognized   $ 4,800 $ 1,300
Allocation of Transaction Price      
Allocation of Transaction Price $ 23,768    
AbbVie Alpha Synuclein Collaboration Agreement | AbbVie | First Development Option Material Right      
Allocation of Transaction Price      
Allocation of Transaction Price 41,232    
AbbVie Alpha Synuclein Collaboration Agreement | Commercial Milestone | AbbVie      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Specified commercial milestone payments $ 500,000